Trial reportScience translational medicine2025
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.
Abstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph
Trial report in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Trial
- Article
- Article
- HIV-1 Env Heterogeneity: Cleavage, Trafficking, and Antigenic Consequences for Virions and Infected Cells.Viruses · 2026Review
- Clade-3 Bat Sarbecovirus PRD0038 Reveals Constraints on Coronavirus Emergence and Immune Sensitivity.Research square · 2026Article
- Rapid boosting increases germinal center responses to sequential vaccines.Nature immunology · 2026Article
- Charting the Path Forward for HIV Immune-Based Prevention: Contributions of the Division of AIDS at NIAID.Vaccines · 2026Article
- Spatiotemporal distribution of SARS-CoV-2 vaccines and vaccine-related proteins in mice and humans.Scientific reports · 2026Article
- Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.Journal of virology · 2026Review
- Beyond Antiretroviral Therapy: Molecular and Immunological Innovations in HIV Treatment.Tropical medicine and infectious disease · 2026Review
- Immunological memory to vaccines.Immunity · 2026Review
- An at-home blood collection device for remote immune monitoring by high-parameter flow cytometry.JCI insight · 2026Article
- Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300).medRxiv : the preprint server for health sciences · 2026Article
- Human immunodeficiency virus vaccines: Advances, challenges and future perspectives.World journal of virology · 2026Review
- Local antibody feedback enforces a checkpoint on affinity maturation in the germinal center and promotes epitope spreading.Immunity · 2026Article
- Virus glycoprotein nanodisc platform for vaccine analytics.Nature communications · 2026Article
- Structure of HIV-1 Env glycoprotein on virions reveals an alternative fusion subunit organization and native membrane coupling.bioRxiv : the preprint server for biology · 2026Article
- GenIV vaccines: bridging innovation to equity in neglected tropical diseases.Frontiers in immunology · 2026Review
- mRNA vaccine platforms and novel delivery systems: From mechanistic principles to clinical translation.Human vaccines & immunotherapeutics · 2025Review
- Nanocarrier-based immunotherapy for viral diseases.International journal of pharmaceutics: X · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors.
K Rachael ParksVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-5307-4455
Zoe MoodieVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-8701-2001
Mary A AllenDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.ORCID 0000-0001-8163-0714
Catherine YenDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA.
Briana D FurchVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-3018-1642
Kellie J MacPheeVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0008-0993-4009
Gabriel OzorowskiDepartment of Integrative, Structural, and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-9695-8138
Jack HeptinstallCenter for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics, and Microbiology, Duke University, Durham, NC 27701, USA.ORCID 0000-0002-3401-5935
William O HahnVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Zihan ZhengVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0005-4070-4621
Huiyin LuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Shannon GrantVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Elize DominDuke University Medical Center, Durham, NC 27701, USA.ORCID 0000-0002-6123-9029
Michael O DuffVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0008-4279-0756
Aaron SeeseVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-5877-6229
Constanza Marini-MacouzetVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Lamar Ballweber-FlemingVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-6180-5545
Wen-Hsin LeeDepartment of Integrative, Structural, and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-9445-6671
Christopher A CottrellCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Scripps Research Institute, La Jolla, CA 92037 USA.ORCID 0000-0002-3364-3083
Alessia LiguoriCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Scripps Research Institute, La Jolla, CA 92037 USA.ORCID 0000-0002-8606-574X
Erik GeorgesonCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Scripps Research Institute, La Jolla, CA 92037 USA.ORCID 0000-0001-5137-4625
Nushin AlaviCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Scripps Research Institute, La Jolla, CA 92037 USA.ORCID 0000-0003-3848-6280
Michael KubitzCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Scripps Research Institute, La Jolla, CA 92037 USA.
Nicole PhelpsCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Scripps Research Institute, La Jolla, CA 92037 USA.ORCID 0000-0001-9613-3921
Kelly E SeatonCenter for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics, and Microbiology, Duke University, Durham, NC 27701, USA.ORCID 0000-0002-2009-3270
Kristen W CohenModerna, 325 Binney Street, Cambridge, MA 02142, USA.ORCID 0000-0002-8901-9941
Maija A AndersonVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Kajari MondalVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0006-2472-2595
Dagna S LauferIAVI, New York, NY 10004, USA.ORCID 0009-0009-6888-8281
James G KublinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-1279-3741
Andrew B WardDepartment of Integrative, Structural, and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7153-3769
Ollivier HyrienVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-1909-2542
Stephen C De RosaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-3871-4618
Sunny HimansuModerna, 325 Binney Street, Cambridge, MA 02142, USA.ORCID 0000-0002-7954-9674
Brett LeavModerna, 325 Binney Street, Cambridge, MA 02142, USA.
Caroline ReuterModerna, 325 Binney Street, Cambridge, MA 02142, USA.ORCID 0009-0005-6083-5717
Georgia D TomarasCenter for Human Systems Immunology, Departments of Surgery, Immunology, Molecular Genetics, and Microbiology, Duke University, Durham, NC 27701, USA.ORCID 0000-0001-8076-1931
David MontefioriDuke University Medical Center, Durham, NC 27701, USA.ORCID 0000-0003-0856-6319
Stephen R WalshDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-0817-9370
Ian FrankDivision of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-7824-0106
Magdalena E SobieszczykDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0002-7112-3118
Paul A GoepfertDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35205, USA.ORCID 0000-0001-8441-5737
Kathryn E StephensonCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-3440-4105
Lindsey R BadenDivision of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Hong Van TieuNew York Blood Center, New York, NY 10017, USA.ORCID 0000-0002-7880-6448
Michael C KeeferInfectious Diseases Division, Department of Medicine, University of Rochester, Rochester, NY 14627, USA.ORCID 0000-0001-9048-3621
Jesse ClarkDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0001-5862-6530
Sharon A RiddlerDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID 0000-0002-2545-7037
William R SchiefCenter for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Scripps Research Institute, La Jolla, CA 92037 USA.ORCID 0000-0002-1120-0150
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0003-2276-7117
Funding
LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6MLC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6MSDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MIdentification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MUniversity of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3MUniversity of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9MVirus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ronald G Collman · 1999 to 2026
$78.6MVirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4MHarvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2MUniversity of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0MUniversity of Pennsylvania HIV Clinical Trials UnitUM1AI069534 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ian Frank, PABLO TEBAS · 2012 to 2026
$33.0MSeattle Vaccine Trials UnitUM1AI069481 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Rachel Ann Bender Ignacio, Margaret Juliana McElrath · 2012 to 2026
$24.4MBill & Melinda Gates Foundation INV-007522Bill & Melinda Gates Foundation INV-008813NCATS NIH HHS UL1 TR001857NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI045008NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI069412NIAID NIH HHS UM1 AI069481NIAID NIH HHS UM1 AI069494NIAID NIH HHS UM1 AI069534NIAID NIH HHS UM1 AI144462
Abstract
mRNA technology might accelerate development of an urgently needed preventive human immunodeficiency virus (HIV) vaccine. We evaluated the safety and immunogenicity of three mRNA-encoded envelope trimers, including two doses of soluble and membrane-anchored forms, in a randomized, open-label, phase 1 clinical trial. Vaccines were generally well tolerated, although 6.5% (7 of 108) of participants developed urticaria, a higher proportion than seen with other mRNA vaccines. mRNA-encoded trimers induced strong envelope-specific B and T cell responses. Immunization with membrane-anchored trimers, intended to obscure epitopes at the trimer base targeted by nonneutralizing antibodies, reduced the frequency of base-binding serum antibodies in comparison with soluble trimers. Three immunizations elicited autologous tier 2 serum neutralizing antibodies in 80% of vaccinees receiving the membrane-anchored trimers, in contrast to only 4% receiving the soluble trimer. Thus, with demonstration of more favorable safety, mRNA-encoded membrane-anchored HIV envelope trimers represent a promising platform for HIV vaccine clinical development.
Indexed as
AIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesProtein MultimerizationRNA, MessengerVaccinationAdultFemaleHIV-1HIV InfectionsHumansMaleMiddle AgedAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesRNA, Messenger
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.